Titre du document / Document title

A comparative analysis of the results from 4 trials of β-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS

Auteur(s) / Author(s)

DOMANSKI Michael J. ; KRAUSE-STEINRAUF Heidi ; MASSIE Barry M. ; DEEDWANIA Prakash ; FOLLMANN Dean ; KOVAR David ; MURRAY David ; OREN Ron ; ROSENBERG Yves ; YOUNG James ; ZILE Michael ; EICHHORN Eric ;

Résumé / Abstract

Background: Recent large randomized, controlled trials (BEST [β-blocker Evaluation of Survival Trial], CIBIS-II [Cardiac Insufficiency Bisoprolol Trial II], COPERNICUS [Carvedilol Prospective Randomized Cumulative Survival Study], and MERIT-HF [Metoprolol Randomized Intervention Trial in Congestive Heart Failure]) have addressed the usefulness of β-blockade in the treatment of advanced heart failure. CIBIS-II, COPERNICUS, and MERIT-HF have shown that β-blocker treatment with bisoprolol, carvedilol, and metoprolol XL, respectively, reduce mortality in advanced heart failure patients, whereas BEST found a statistically nonsignificant trend toward reduced mortality with bucindolol. We conducted a post hoc analysis to determine whether the response to β-blockade in BEST could be related to differences in the clinical and demographic characteristics of the study populations. We generated a sample from BEST to resemble the patient cohorts studied in CIBIS-II and MERIT-HF to find out whether the response to β-blocker therapy was similar to that reported in the other trials. These findings are further compared with COPERNICUS, which entered patients with more severe heart failure. Methods: To achieve conformity with the entry criteria for CIBIS-II and MERIT-HF, the BEST study population was adjusted to exclude patients with systolic blood pressure <100 mm Hg, heart rate <60 bpm, and age >80 years (exclusion criteria employed in those trials). The BEST comparison subgroup (BCG) was further modified to more closely reflect the racial demographics reported for patients enrolled in CIBIS-II and MERIT-HF. The association of β-blocker therapy with overall survival and survival free of cardiac death, sudden cardiac death, and progressive pump failure in the BCG was assessed. Results: In the BCG subgroup, bucindolol treatment was associated with significantly lower risk of death from all causes (hazard ratio (HR) = 0.77 [95% CI = 0.65, 0.92]), cardiovascular death (HR = 0.71 [0.58, 0.86]), sudden death (HR = 0.77 [0.59, 0.999]), and pump failure death (HR = 0.64 [0.45, 0.91]). Conclusions: Although not excluding the possibility of differences resulting from chance alone or to different properties among β-blockers, this study suggests the possibility that different heart failure population subgroups may have different responses to β-blocker therapy.

Revue / Journal Title

Journal of cardiac failure    ISSN  1071-9164 

Source / Source

2003, vol. 9, n^o5, pp. 354-363 [10 page(s) (article)]

Langue / Language

Anglais

Editeur / Publisher

Elsevier, Orlando, FL, ETATS-UNIS  (1994) (Revue)

Localisation / Location

INIST-CNRS, Cote INIST : 27048, 35400011868073.0010